Accelerating Discovery of Leukemia Inhibitors Using AI-Driven Quantitative Structure-Activity Relationship: Algorithm Development and Validation.

backgroundLeukemia treatment remains a major challenge in oncology. While thiadiazolidinone analogs show potential to inhibit leukemia cell proliferation, they often lack sufficient potency and selectivity. Traditional drug discovery struggles to efficiently explore the vast chemical landscape, highlighting the need for innovative computational strategies. Machine learning (ML)-enhanced quantitative structure-activity relationship (QSAR) modeling offers a promising route to identify and optimize inhibitors with improved activity and specificity.

objectiveWe aimed to develop and validate an integrated ML-enhanced QSAR modeling workflow for the rational design and prediction of thiadiazolidinone analogs with improved antileukemia activity by systematically evaluating molecular descriptors and algorithmic approaches to identify key determinants of potency and guide future inhibitor optimization.

methodsWe analyzed 35 thiadiazolidinone derivatives with confirmed antileukemia activity, removing outliers for data quality. Using Schrödinger MAESTRO, we calculated 220 molecular descriptors (1D-4D). Seventeen ML models, including random forests, XGBoost, and neural networks, were trained on 70% of the data and tested on 30%, using stratified random sampling. Model performance was assessed with 12 metrics, including mean squared error (MSE), coefficient of determination (explained variance; R

resultsIsotonic regression ranked first with the lowest test MSE (0.00031 ± 0.00009), outperforming baseline models by over 15% in explained variance. Ensemble methods, especially LightGBM and random forest, also showed superior predictive performance (LightGBM: MSE=0.00063 ± 0.00012; R

conclusionsIntegrating advanced ML with QSAR modeling enables systematic analysis of structure-activity relationships in thiadiazolidinone analogs on this dataset. While ensemble methods capture complex patterns with high internal validation metrics, external validation on independent compounds and prospective experimental testing are essential before broad therapeutic claims can be made. This work provides a methodological foundation and identifies molecular features for future validation efforts.